Some Considerations on HLA and Malignancies

  • Jean Dausset
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 57)


At the beginning of this conference, it is certainly worthwhile to survey our present knowledge of the possible association or linkage between human malignancies and the most powerful and polymorphic marker: the HLA system. Indeed a considerable number of studies have been carried out since the first two studies done in France on acute lymphoblastic leukemia1 and Hodgkin’s disease2.


Acute Lymphoblastic Leukemia Nasopharyngeal Carcinoma Fanconi Syndrome Intestinal Polyposis Familial Melanoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    F. M. Kourilsky, J. Dausset, N. Feingold, J. M. Dupuy and J. Bernard, Etude de la repartition des antigènes leucocytaires chez des malades atteints de leucémie aiguë en remission, in: “Advance in Transplantation,” Munksgaard, Copenhagen (1967).Google Scholar
  2. 2.
    J. L. Amiel, E. S. Curtoni, P. L. Mattiuz and R. M. Tosi, Study of the leukocyte phenotypes in Hodgkin’s disease, in: “Histocompatibility Test. 67”.Google Scholar
  3. 3.
    J. Dausset and A. Svejgaard (eds), “HLA and Disease,” Munksgaard, Copenhagen (1977).Google Scholar
  4. 4.
    L. P. Ryder, E. Andersen and A. Svejgaard (ed), “HLA and Disease Registry,” Munksgaard, Copenhagen (1979).Google Scholar
  5. 5.
    “HLA and Malignancy,” G.P. Murphy, ed., Alan R. Liss, New York (1977).Google Scholar
  6. 6.
    L. Degos, M. Pla and J. Colombani, H2 restriction for lymphocyte homing into lymph nodes, Eur. J. Immunology 9: 808 (1979).CrossRefGoogle Scholar
  7. 7.
    J. Dausset, HLA and association with malignancy: A critical view, in: “HLA and Malignancy,” G. P. Murphy, ed., Alan R. Liss, New York (1977).Google Scholar
  8. 8.
    W. E. Braun, “HLA and Diseases: A comprehensive review,” CRC Press Inc., Boca Raton, Florida (1979).Google Scholar
  9. 9.
    L. P. Ryder, C. Dam-Soerengen and A. Svejgaard, “4th Edition of the HLA and Disease Registry,” Copenhagen (in press).Google Scholar
  10. 10.
    E. D. Albert, B. Nisperos and E. D. Thomas, HLA antigens and haplotypes in acute leukemia, Leukemia Res. 1: 4: 261 (1977).CrossRefGoogle Scholar
  11. 11.
    G. N. Rogentine, R. J. Trapani, R. A. Yankee and E. S. Henderson, HLA antigens and acute lymphocytic leukemia: the nature of the HL-A2 association, Tissue Antigens 3: 470 (1973).CrossRefGoogle Scholar
  12. 12.
    J. Dausset and J. Hors, Some contributions of the HLA complex to the genetics of human disease, Transf. Rev. 22: 44 (1975).Google Scholar
  13. 13.
    T. Tursz, J. Hors, M. Lipinski and J. L. Amiel, HLA phenotypes in long-term survivors treated with BCG immunotherapy for childhood ALL, Brit. Med. J. 1: 1250 (1978).CrossRefGoogle Scholar
  14. 14.
    J. Falk and D. Osoba, The HLA system and survival in malignant disease: Hodgkin’s disease and carcinoma of the breast, in: “HLA and Malignancy,” (ref. 5).Google Scholar
  15. 15.
    M. J. Simons, G. B. Wee, S. H. Chan, K. Shanmugaratuam, N. E. Day and G. de The, Probable identification of an HLA second locus antigen associated with high risk of nasopharyngeal carcinoma, Lancet 1: 142 (1975).CrossRefGoogle Scholar
  16. 16.
    H. Betuel, M. Camoun, J. Colombani, N. E. Day, R. Ellouz and G. de Thé, The relationship between nasopharyngeal carcinoma and the HL-A system among Tunisians, Int. J. Cancer 16: 249 (1975).Google Scholar
  17. 17.
    A. Lanier, T. Bender, M. Talbot, S. Wilmeth, C. Tschopp, W. Henle, G. Henle, D. Ritter and P. Terasaki, Nasopharyngeal cancer in Alaskan Eskimos, Indians and Aleuts: a review of cases and studies of EBV, HLA and environmental risk factors, Cancer 46: 2100 (1980).CrossRefGoogle Scholar
  18. 18.
    H. Chan, N. E. Day, T. H. Khor, N. Kunaratnam and K. B. Chia, HLA markers in the development and prognoses of NPC in disease, in.: “Cancer Campaign,” vol. 5, Gustar Fischer Verlag, Stuttgart, New York (1981).Google Scholar
  19. 19.
    M. E. Kuntz, G. D. Schmidt, S. Scholz and E. D. Albert, HLA antigens and hypernephroma, Tissue Antigens 12: 407 (1978).CrossRefGoogle Scholar
  20. 20.
    B. Cavelier, M. Daveau, D. Gilbert, M. Fontaine, J. P. Cesarini and B. Delpech, Augmentation de l’antigene HLA-A9 dans les melanomes malins, principalement dans les formes metastiques ou les recidives. A propos de 105 melanomes dont 34 formes graves, CR Acad. Sci. 291: 241 (1980).Google Scholar
  21. 21.
    N. Rogentine and P. B. Dellon, Prolonged disease-free survival in bronchogenic carcinoma associated with HLA Aw19 and B5: A follow-up, Ier Int. Symp. on HLA and Disease, INSERM, Paris (1976).Google Scholar
  22. 22.
    J. Dausset, E. Gluckman, F. Lemarchand, A. Nunez-Roldan, L. Contu and J. Hors, Exces de HLA-A2 parmi les malades atteints d’aplasie medullalre et maladie de Fanconi, N. Rev. Fr. d’Hemat. 18: 315 (1977).Google Scholar
  23. 23.
    A. Blattner, J. L. Naiman, D. L. Mann, R. S. Wimer, J. H. Dean and J. F. Fraumeni, Immunogene tic determinants of familial ALL, Ann. Int. Med. 89: 173 (1978).CrossRefGoogle Scholar
  24. 24.
    E. Maldonado, H. F. Taswell and J. M. Kiely, Familial Hodgkin’s disease, Lancet 2: 1259 (1972).CrossRefGoogle Scholar
  25. 25.
    A. McBride and J. J. Fennelly, Immunological depletion contributing to familial Hodgkin’s disease, Eur. J. Cancer 13: 549 (1977).CrossRefGoogle Scholar
  26. 26.
    K. Bowers, C. F. Moldow, C. D. Bloomfield and E. J. Yunis, Familial Hodgkinfs disease and the major histocompatibility complex, Vox Sanguinis 33: 273 (1977).CrossRefGoogle Scholar
  27. 27.
    A. Nagel, E. Nagel-Studer, W. Seiler and H. O. Hofer, Malignant lymphoma In four of five siblings, Int. J. Cancer 22: 675 (1978).CrossRefGoogle Scholar
  28. 28.
    H. Greene, E. A. McKeen, F. P. Li, W. A. Blattner and J. F. Fraumeni, HLA antigens in familial Hodgk inT s disease, Int. J. Cancer 23: 777 (1979).CrossRefGoogle Scholar
  29. 29.
    A. Torres, F. Martinez, P. Gomez, C. Gomez, J. M. Garcia and A. Nunez-Roldan, Simultaneous Hodgkin’s disease in three siblings with identical HLA genotype, Cancer 46: 838 (1980).CrossRefGoogle Scholar
  30. 30.
    J. Hors, G. Steinberg, J.M. Andrieu, C. Jacquillat, M. Minev, J. Messerschmitt, G. Malinvaud, F. Fumeron and J. Dausset, HLA genotypes in familial Hodgkin’s disease. Excess of HLA identical affected sibs, Eur. J. Cancer 16: 809 (1979).Google Scholar
  31. 31.
    B. R. Hawkins, R. L. Dawkins, A. Hockey, J. B. Houliston and R. L. Kirk, Eyidence for linkage between HLA and malignant melanoma, Tissue Antigens 17: 540 (1981).CrossRefGoogle Scholar
  32. 32.
    J. P. Cesarini, M. Daveau, B. Cavelier, N. Feingold, P. Puissant, F. Fumeron and J. Hors, More arguments in favor of a linkage between HLA and susceptibility to malignant melanoma (in preparation).Google Scholar
  33. 33.
    D. Rovini, M. T. Illeni, A. Ghidoni, M. Vaglini, E. Privitera, G. Pellegris and N. Cascinelli, HLA antigens in familial melanoma patients, 6th Int. Cong. Human Genetics, Jerusalem (1981).Google Scholar
  34. 34.
    N. Dupré, E. Nouzha, C. Raffoux, J. C. Morvan and J. P. Gras, Polypose rectocolique familiale et système HLA. A propos d’une observation, Bordeaux Medical 30: 2125 (1977).Google Scholar
  35. 35.
    T. Sasazuki, H. Kaneoka, Y. Nishimura, R. Kaneoka, M. Hayama and H. Ohkuni, An HLA-linked immune suppression gene in man, J. Exp. Med. 152: 2: 297 (1980).Google Scholar
  36. 36.
    D. Rosner, E. Cohen, S. G. Gregory, U. Khurana and C. Cox, Breast cancer and HLA relationship in a high risk family, in: “HLA and Malignancy,” (ref. 5).Google Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • Jean Dausset
    • 1
  1. 1.Hôpital Saint-LouisParisFrance

Personalised recommendations